泽布替尼治疗异基因造血干细胞移植后中枢神经系统移植后淋巴细胞增殖性疾病：一例报告
Zanubrutinib Treatment of Central Nervous System Posttransplant Lymphoproliferative Disorder After Allogeneic Hematopoietic Stem Cell Transplantation: A Case Report.
作者信息
Yang Ting-Ting, Chen Wei-Hao, Zhao Yan-Min, Fu Hua-Rui, Huang He, Shi Ji-Min
机构信息
Bone Marrow Transplantation Center, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
Institute of Hematology, Zhejiang University, Hangzhou, China.
出版信息
Front Oncol. 2021 Apr 29;11:672052. doi: 10.3389/fonc.2021.672052. eCollection 2021.
Posttransplant lymphoproliferative disorder (PTLD) is a rare complication after allogeneic hematopoietic stem cell transplantation (allo-HSCT) with poor prognosis. We report a patient with PTLD involved central nervous system (CNS) who treated with zanubrutinib, a second-generation Bruton tyrosine kinase (BTK) inhibitor. Our report supports the efficacy of bruton tyrosine kinase inhibitor zanubrutinib in the treatment of CNS-PTLD, which provides a new therapeutic option.
移植后淋巴细胞增殖性疾病（PTLD）是异基因造血干细胞移植（allo-HSCT）后一种罕见的并发症，预后较差。我们报告了一例累及中枢神经系统（CNS）的PTLD患者，该患者接受了第二代布鲁顿酪氨酸激酶（BTK）抑制剂泽布替尼治疗。我们的报告支持布鲁顿酪氨酸激酶抑制剂泽布替尼治疗中枢神经系统PTLD的疗效，这提供了一种新的治疗选择。
Zotero 插件